HUTCHMED (China) (HMDCF) Profit After Tax (2015 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Profit After Tax came in at -$198.9 million in Q4 2021, down 251.6% quarter-over-quarter from $131.2 million in Q3 2021.
Analysis
HUTCHMED (China) (HMDCF) Profit After Tax (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Profit After Tax for 6 consecutive years, with -$198.9 million the latest figure, recorded in Q4 2021.
- On a quarterly basis, Profit After Tax changed N/A year-over-year to -$198.9 million in Q4 2021; TTM through Dec 2021 was -$167.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $456.9 million, up 1111.03% from the prior year.
- Profit After Tax was -$198.9 million for Q4 2021 at HUTCHMED (China), down from $131.2 million in the prior quarter.
- Over five years, Profit After Tax peaked at $180.7 million in Q4 2019 and troughed at -$198.9 million in Q4 2021.
- A 4-year average of -$2.7 million and a median of -$12.9 million in 2018 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 1047.54% in 2019, down 254.36% in 2019.
- Over 4 years, Profit After Tax stood at $15.7 million in 2018, then soared by 1047.54% to $180.7 million in 2019, then sank by 118.16% to -$32.8 million in 2020, then slumped by 506.08% to -$198.9 million in 2021.
- The last three Profit After Tax figures came in at -$198.9 million (Q4 2021), $131.2 million (Q3 2021), and -$59.5 million (Q2 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -290.61 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -198.92 Mn |
| Sep 28, 2021 | 131.22 Mn |
| Jun 30, 2021 | -59.49 Mn |
| Mar 31, 2021 | -39.85 Mn |
| Jun 30, 2020 | -32.82 Mn |
| Mar 31, 2020 | -15.43 Mn |
| Dec 31, 2019 | 180.72 Mn |
| Sep 30, 2019 | -31.24 Mn |
| Jun 30, 2019 | -62.56 Mn |
| Mar 31, 2019 | 19.11 Mn |
| Dec 31, 2018 | 15.75 Mn |
| Sep 30, 2018 | 25.41 Mn |
| Jun 30, 2018 | 40.53 Mn |
| Mar 31, 2018 | -10.41 Mn |
| Jun 30, 2016 | 29.56 Mn |
| Jun 30, 2015 | 23.49 Mn |